Fintech PR
Westbourne River Partners letter to Biotest AG
LONDON, April 15, 2025 /PRNewswire/ — Westbourne River Partners letter to Biotest AG with respect to the delisting offer made by Grifols S.A. to shareholders of Biotest:
Biotest AG
Attn. Peter Jannsen
Landsteinerstr. 5
D-63303 Dreieich
Cc: Supervisory Board
Dear Peter,
We are writing to you on behalf of Westbourne River Event Master Fund (“Westbourne River” or “we”), the largest minority shareholder in Biotest AG (“Biotest” or the “Company”), with respect to the delisting offer made by Grifols S.A. (“Grifols”) to shareholders of the Company. We are deeply concerned about the decision of the management board to support the delisting, and we ask that the management and supervisory boards consider the appropriateness of (A) the decision to delist and (B) the price at which the delisting offer has been made.
At their investor event in February 2025, Grifols clearly stated that it would like to integrate Biotest into their larger operations. The simplest means for Grifols to accomplish this, given their 97% voting control of the Company, would be to launch a domination agreement. Indeed, the only structural measures available under German law for Grifols to achieve “integration” are (1) a squeeze-out (which would require Grifols to obtain a minimum of 90% of the Company’s total capital) or, more realistically, (2) a domination agreement. Without undertaking one of these measures, Biotest will continue to be required to operate on an arm’s length basis with Grifols.
Instead, Grifols are pursuing a delisting. On its face, and as described in further detail below, this strikes us as an attempt to scare minority shareholders into tendering their shares at below fair value, and to significantly hamper minority shareholders from monitoring the Company’s progress and business plan ahead of an eventual undertaking of one of the structural measures outlined above.
Delisting will not achieve Grifols’s goal of integration. Delisting will, however, reduce the disclosure obligations of the Company and the transparency into the Company’s business that minority shareholders currently have. Given the lack of liquidity in Biotest ordinary and preference shares, Grifols would be required to instruct an IDW-S1 valuation that would value the Company based on its own business plan for either a squeeze-out or a domination agreement. We firmly believe that valuation would be significantly above the stock market price. The lack of transparency that would come with delisting ahead of undertaking one of these measures would leave minority shareholders largely in the dark with respect to the business plan and resulting valuation. As such, delisting carries the very real threat of being harmful to minority shareholders.
In early February 2025, Grifols – represented by its board member, Tomas Daga – reached out to us and offered to buy our stake in Biotest. When we suggested that they should use the structural measures available to them under German law, Mr. Daga dismissed this option, stating that Grifols didn’t want to go through a valuation exercise and guarantee dividends. Instead, he asserted that they were going to delist the Company, and that our options were therefore either to sell our stake now or to remain in a private vehicle following the delisting. As you are aware, we immediately relayed this conversation, our concerns and a request to oppose a delisting offer to the Chairman of the supervisory board via phone and email, who assured us in response that Biotest “(took) the matter very seriously”.
Now, less than two months later, the fact that the management board, which you chair, has already entered into a delisting agreement with Grifols is extremely disappointing and suggests that the Chairman of the supervisory board’s reassurance in February was an empty one. This reinforces our long-held concern that the Company is acting in the interest of its majority shareholder rather than in the interest of all shareholders. Two recent examples further highlight the basis for these concerns:
First, in November 2024, Biotest’s cash flow guidance implied a €50-80 million cash burn in Q4 2024. However, the actual FY 2024 results, published in February 2025, indicated a cash inflow of roughly €40 million in that period. In other words, approximately €100 million of outperformance versus Company guidance given just seven weeks prior to the end of the year. In the interim period, Mr. Daga made us the offer described above at €30 per preference share. He justified the low bid by significantly disparaging the Company and its management and referring to the expected significant cash burn. Had the Company’s original guidance been similar to its actual ultimate performance, this argument about cash burn would have been obviously spurious.
Second, on 31 March 2025 – the same day as the announcement of the delisting offer – the Company released guidance indicating an operating loss in 2025 of over €55 million. This guidance stands in stark contrast to the Company’s operating profit in 2024 of €95 million. Despite our questions during the full-year earnings call and requests for a detailed explanation, we have received no satisfactory answers explaining an expected €150 million decrease in year-over-year operating profits.
Without any other reasonable explanations, we are left to fear that the Company’s management board is making unjustifiably conservative projections that may have a manipulative effect on the stock price and, if and when Grifols launch a squeeze-out or domination agreement process, would materially reduce the IDW-S1 valuation process and serve Grifols to the detriment of other shareholders. This is particularly relevant now as Biotest is about to launch Fibrinogen and is progressing with the phase-III trial of Trimodulin. In Grifols’ own words, these products are expected to have a market opportunity of over $800 million and over $2 billion, respectively. According to Grifols’ analysts’ comments published following the delisting offer, Grifols is making the offer now to buy out minority shareholders at a cheap price ahead of progression of these products, which is expected to substantially increase Biotest’s valuation.
Without the fulsome disclosure requirements of a listed company, minority shareholders would be far less able to track and compare the Company’s projections and results versus prior results and public commentary (both by itself and by Grifols regarding Biotest’s business) and would therefore be unable to call attention to practices that appear to unfairly harm minority shareholders. In other words, if, in the future, the Company were to produce artificially conservative business plans under a new reduced disclosure requirement, it would be more difficult to discover and hold the Company to account.
For these reasons, we ask that the Company reconsider the appropriateness of delisting, especially if the prices of the delisting offer remain unchanged.
As indicated, we also view the terms of the offer as being made at a price materially less than fair value. When Grifols made a takeover offer for the Company in 2021, they agreed to pay €43 per ordinary share and €37 per preference share. Given that the economic rights of the preference shares and the ordinary shares are the same, we believed at the time (and still believe) that the value of these shares should be the same. Indeed, an IDW-S1 valuation would likely value the preference shares and ordinary shares at the same level.
Even if one assumes that the ordinary shares carry a higher value than the preference shares (which, as described above, would likely not be the case in an IDW-S1 valuation), it is clear from Grifols’s own statements that they believe (like we do) that Biotest has made significant progress in the intervening years. Presumably, then, further value will have accrued to the Company, and the current value of the company should be at a significant premium to the price Grifols paid in 2021, for both share classes. Instead, we find Grifols offering the same price per ordinary share as they offered in 2021, and 19% less per preference share. We don’t believe that there is any fundamentals-based rationale for such a valuation.
Ostensibly, Grifols is launching the offer for preference shares at the statutory minimum price. Grifols’ shareholding has increased since the end of 2024. We were approached with an offer to buy our stake at €30 per preference share. We understand that other large minority shareholders were approached with the same offer, and that Grifols were in fact able to acquire additional shares this year at €30 per preference share. This likely defines the statutory minimum they would need to pay for a delisting offer. Several boards supporting delisting offers in the last few years have argued in favor of these offers on the basis that they provide exit liquidity for shareholders. Here, this argument doesn’t apply: we understand that Grifols has contacted other shareholders in the way they have contacted us. If that is the case, shareholders will have already had the opportunity to sell at €30 per preference share this year. This delisting offer therefore has no value for current shareholders who rejected Grifols’ €30 offer. Remaining shareholders would lose value by accepting the delisting offer, which we believe is below fair market value. Those who want to dispose of their Biotest shares at depressed prices can do so on the stock exchange.
Despite the lack of benefit – and the clear potential for harm – to minority shareholders, your board has agreed to support the delisting offer. What’s more, you have done so in the absence of any formal fair value assessment. We believe this could indicate a lack of independence and a dereliction of the duties that both the management board and the supervisory board owe to all shareholders. Supporting an unfairly priced delisting offer is akin to supporting a below market value squeeze-out for those shareholders who must not hold unlisted equity. In our view, this would be a breach of the Biotest boards’ fiduciary duties, at least with respect to minority shareholders.
We would ask the boards of Biotest to withdraw their support for the delisting unless the offer price is increased to an IDW-S1-supported valuation, which is in turn based on a reasonable business plan. Further, the Company should clearly outline their mid-term plan and earnings potential, including the ramp up of Trimodulin production, and increase their shareholder outreach to ensure every shareholder has the same information about the Company’s prospects.
Yours Sincerely,
Abhishek Agrawal
Senior Portfolio Manager
Westbourne River Partners
Media Contact
pro-westbourneriver@prosek.com
+44 20 3890 9193
View original content:https://www.prnewswire.co.uk/news-releases/westbourne-river-partners-letter-to-biotest-ag-302427907.html
Fintech PR
Okto Becomes Go-To DeFi Trading App in Korea with Hyperliquid Spot & Futures Integration, HyperEVM launching soon
BANGALORE, India, April 23, 2025 /PRNewswire/ — Okto, the mobile frontend for Hyperliquid, has rapidly emerged as the preferred choice for Korean crypto investors, offering seamless access to Hyperliquid’s Spot and Futures markets — all within a single, self-custodial mobile interface. With deep liquidity, low slippage, and advanced trading infrastructure, Hyperliquid has become one of the most powerful decentralized trading venues. Okto acts as its mobile front end, combining CEX-like performance with the security and control of self-custody, allowing Korean traders to experience the full power of DeFi without friction.
“Korean investors are leading the next wave of DeFi adoption,” said Rohit Jain, Head of DeFi Initiatives at Okto. “The rise in perpetual and spot trading activity on the Hyperliquid-powered Okto app is proof that the region is embracing decentralized markets — not as an alternative, but as the future. With self-custody at the core and institutional-grade liquidity, Okto is helping redefine how Korean trades.”
Okto’s Futures trading went live in February 2024, followed by the recent launch of Spot trading — marking yet another major milestone in the app’s rapid evolution. “We envision Okto as the ‘Phantom’ of Hyperliquid — the most seamless and secure mobile gateway for decentralized trading,” said Rohit Jain. “As the leading mobile app for Hyperliquid, Okto was the first to integrate both Futures and Spot trading, and will soon be the first to bring HyperEVM assets and dApps directly to users. With this, we anticipate exponential growth in adoption over the next 2–3 years.”
Key Features:
- Hyperliquid-Optimized Design: Okto is tailored to integrate seamlessly with Hyperliquid’s advanced tools, allowing traders to manage their positions effortlessly across both spot and futures wallets. The one-click deposit feature to the Hyperliquid Spot wallet eliminates prior steps required for transactions on Hyperliquid.
- Cross-Chain Trading: With Okto’s powerful chain abstraction, users can seamlessly deposit and manage assets across 5+ blockchain networks — including Solana, Ethereum, Polygon, and more — all within a single app. Thanks to the Okto Layer, a robust middleware that abstracts away Web3 complexities, traders can now bring assets in and out of Hyperliquid with just one click. This unlocks true cross-chain trading at scale, maximizing opportunities without the friction of manual bridging or multiple wallets.
- Enhanced Security & Control: Okto offers a self-custodial wallet, providing users full control over their assets. Secure, gasless transactions and social login options enhance user convenience.
- Smart Notifications: Receive real-time alerts for price movements, trade execution, and market updates, ensuring traders never miss important opportunities.
- Optimized Mobile Experience: Designed with a mobile-first approach and CEX like experience, Okto eliminates friction in decentralized trading by offering real-time portfolio tracking and one-click cross-chain swaps, giving users greater flexibility.
Okto is revolutionizing mobile DeFi trading, making institutional-grade DEX trading accessible directly from users’ mobile devices. Whether a seasoned trader or a DeFi newcomer, Okto offers a secure, intuitive, and rewarding platform to access Hyperliquid’s full potential.
About Okto
The Okto ecosystem aims to simplify Web3 for everyone. At its core, it is a chain abstraction, and orchestration layer designed to simplify blockchain development. By offering web2-like modular APIs to help both new developers and experienced teams to build efficiently on the blockchain.
Okto ecosystem is experienced by 20Mn+ users while under development in the pre mainnet phase. Key components include the Okto Chain, Okto SDK, Okto wallet and Okto partners ecosystem.
Logo: https://mma.prnewswire.com/media/2625238/5179517/Okto_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/okto-becomes-go-to-defi-trading-app-in-korea-with-hyperliquid-spot–futures-integration-hyperevm-launching-soon-302435299.html
Fintech PR
Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg
TOKYO, April 23, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis, in addition to an investment of approximately JPY 15.9 million (USD 0.1 million1) for a drug discovery project for Chagas disease and leishmaniasis.2
Investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis
Tuberculosis (TB) remains a serious infectious disease, with approximately 10.8 million cases and 1.25 million deaths reported in 2023, making it the leading causes of death from a single infectious agent.3 The United Nations’ Sustainable Development Goals (SDGs) set a target to end TB by 2030, but achieving this goal requires accurate and accessible diagnostic technologies. Current TB tests face challenges such as low sensitivity, high costs, complexity, and the need for specialized equipment and sputum samples, making them unsuitable for all patients. In particular, children, people with conditions who cannot produce sputum, and those in resource-limited settings often struggle to receive timely diagnoses, causing the continued spread of the disease. To address this issue, the GHIT Fund has decided to invest approximately JPY 679 million (USD 4.5 million1) towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, Inc., 4 in partnership with Fujirebio, Inc., a developer of clinical diagnostics in Japan,4 and Heidelberg University Hospital in Germany.
This project will leverage Fluxus’ cutting-edge ultrasensitive detection technology to develop and validate a urine-based TB biomarker lipoarabinomannan (LAM) assay on its automated benchtop immunoassay analyzer. Additionally, the project will design and develop critical components for a portable, ultrasensitive point-of-care (PoC) system that integrates the urine LAM test. This advanced technology will enable rapid, accurate, and accessible diagnosis across a broader patient population, contributing to improved clinical outcomes and reduced transmission.
In addition, the GHIT Fund will invest approximately JPY 15.9 million (USD 0.1 million1) in a screening project against Chagas disease and leishmaniasis by Kitasato University, Nagasaki University, University of Tokyo, and Drugs for Neglected Diseases initiative (DNDi).
Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.
As of March 31, 2025, the GHIT Fund has invested in 36 projects, including 15 discovery projects, 12 preclinical projects, and 9 clinical trials.5 The total amount of investments since 2013 is JPY 38.2 billion (USD 255 million1) (Appendix 2).
1 USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002 and RFP2024-001 for the Product Development Platform and the Screening Platform, which were open for applications from June 2023 to July 2024.
3 WHO: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
4 Fluxus, Inc. and Fujirebio, Inc. are members of Fujirebio.
5 This number includes projects in the registration phase.
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en
Appendix 1. Project Details
ID: G2023-204
|
Project Title |
Ultrasensitive Detection of Urine LAM for Point-of-Care Rapid Diagnosis of All Forms |
|
Collaboration Partners |
1. Fluxus, Inc. (USA) 2. Fujirebio, Inc. (Japan) 3. Heidelberg University Hospital (Germany) |
|
Disease |
Tuberculosis |
|
Intervention |
Diagnostics |
|
Stage |
Product Design, Product development |
|
Awarded Amount |
JPY 679,783,110 (USD 4.54 million) |
|
Status |
New project |
|
Summary |
[Project objective] To develop a prototype portable point-of-care (PoC) system and integrated ultrasensitive
[Project design] |
|
Project Detail |
https://www.ghitfund.org/investment/portfoliodetail/detail/240/en |
ID: S2024-122
|
Project Title |
Searching for Chagas disease therapeutic seed compounds from microbial cultures |
|
Collaboration Partners |
1. Kitasato University (Japan) 2. Nagasaki University (Japan) 3. University of Tokyo (Japan) 4. Drugs for Neglected Diseases initiative (DNDi) (Switzerland) |
|
Disease |
Chagas disease / Leishmaniasis |
|
Intervention |
Drug |
|
Stage |
Screening |
|
Awarded Amount |
JPY 15,945,864 (USD 106,639) |
|
Status |
New project |
|
Summary |
[Project objective] The main objective of our proposed project is to identify novel T. cruzi active scaffolds
[Project design] |
|
Project Detail |
https://www.ghitfund.org/investment/portfoliodetail/detail/241/en |
*All amounts are listed at an exchange rate of USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.
Appendix 2. Investment Overview (as of March 31, 2025)
Investments to date
Total investments: 38.2 billion yen (USD 255 million1)
Total invested projects: 136 (36 active projects and 100 completed projects)
To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en
For more information, contact:
Katy Lenard at +1-301-280-5719 or klenard@burness.com
Mina Ohata at +81-36441-2032 or mina.ohata@ghitfund.org
Fintech
Fintech Pulse: Your Daily Industry Brief – April 22, 2025 (Fiserv, Circle, Braviant, ANNA Money & Shaype, Yubi)
In today’s rapidly evolving financial technology landscape, incumbents and challengers alike are pushing the boundaries of what’s possible—from regional expansion and payments network advancements to credit infrastructure innovations and AI‑powered super apps. Here’s your concise yet comprehensive op‑ed–style rundown of the day’s most impactful developments.
1. Fiserv Plants Its Flag in the Heartland
Overview: Milwaukee‑based Fiserv has officially confirmed that it will invest $125 million to renovate two buildings on Aspiria campus in Overland Park, Kansas, establishing a 2,000‑employee regional headquarters by March 2030. The new hub, dubbed “Project Turtle,” will transform 427,000 sq ft of former Sprint space into a strategic fintech nexus.
Source: KSHB 41 Kansas City News
Analysis & Opinion:
-
Strategic Geography: Kansas City’s burgeoning tech talent pool and central U.S. location make Aspiria an ideal crossroads for Fiserv’s expansion, signaling that regional cost structures and quality‐of‐life factors are increasingly drawing fintech giants away from coastal hubs.
-
Talent & Economics: Pledging an average salary of $125,000, Fiserv’s commitment underscores the fierce competition for skilled technologists outside traditional metros. Local incentives—property tax rebates and clawback provisions—reflect how states are sharpening their playbooks to attract large fintech employers.
-
Implications for Fintech Clusters: As Fiserv’s new campus joins other high‑tech projects (e.g., Panasonic EV batteries in De Soto), the Kansas City area is rapidly becoming a Midwest fintech cluster, offering a blueprint for similar “second‑tier” cities vying for innovation dollars.
2. Circle Unveils a Global Payments Network on Stablecoins
Overview: Circle Internet Group announced the Circle Payments Network (CPN), a platform leveraging regulated stablecoins (USDC, EURC) to facilitate 24/7 real‑time settlement of cross‑border payments for banks, neo‑banks, and payment service providers. Governance partners include Santander, Deutsche Bank, Société Générale, and Standard Chartered.
Source: Press Release Hub
Analysis & Opinion:
-
Cross‑Border Friction Points: With traditional remittances still averaging >6% fees and multi‑day settlement times, CPN’s programmable rails promise to undercut correspondent‑bank fees and compliance bottlenecks, particularly in emerging markets.
-
Institutional Trust & Compliance: By imposing strict AML/CFT, licensing, and cybersecurity prerequisites, Circle addresses one of the biggest barriers to stablecoin adoption among regulated institutions—namely, the fear of regulatory backlash.
-
Developer Ecosystem: The modular API architecture invites third‑party integrations, foreshadowing an “app store” of financial workflows. This opens new revenue streams for Circle and positions CPN as a foundational layer for decentralized finance (DeFi) interoperability among legacy institutions.
3. Braviant Charts a New Course for Financial Access
Overview: Braviant Holdings, marking its 10th anniversary in consumer credit innovation, has unveiled a multi‑pronged strategy to deepen partnerships with investors, lenders, vendors, and service providers, aiming to broaden access to alternative credit for the underbanked.
Source: PR Newswire
Analysis & Opinion:
-
Underbanked Market Focus: With the FDIC estimating 51.1 million underbanked U.S. adults and 33% of consumers sporting non‑prime credit scores, Braviant’s data‑driven underwriting and digital borrowing experience could finally bridge gaps left by traditional scoring models.
-
Strategic Alliances: By courting a wider circle of financial service providers, Braviant looks to embed its analytics engine into partner workflows—transitioning from a standalone lender to a B2B2C platform.
-
Sustainable Growth vs. Regulatory Scrutiny: As regulatory bodies intensify oversight of alternative lenders, transparency in Braviant’s innovative analytics will be as crucial as technological prowess in securing long‑term viability.
4. ANNA Money & Shaype Launch Australia’s First AI‑Powered Finance “Super App”
Overview: UK‑based ANNA Money, in partnership with embedded finance provider Shaype, has rolled out the first AI‑driven “business finance super app” tailored for Australian Pty Ltd companies. The platform consolidates banking, tax (IAS/BAS) prep, expense tracking, company formation, and corporate cards into a single interface.
Source: IBS Intelligence, PR Newswire
Analysis & Opinion:
-
End of Fragmented Workflows: SMEs have long cobbled together disparate tools—accounting software, bank portals, expense apps—resulting in data silos. ANNA’s unified approach can slash admin time and elevate financial visibility.
-
AI‑Driven Decisioning: Real‑time transaction categorization and predictive cash‑flow insights give business owners a 24/7 financial co‑pilot, potentially reducing reliance on external advisors for routine tasks.
-
Embedded Finance Leapfrog: By leveraging Shaype’s infrastructure, ANNA bypasses lengthy integrations, showcasing how embedded finance partnerships accelerate time‑to‑market for super apps.
5. Yubi & Cockroach Labs Power Next‑Gen Credit Infrastructure
Overview: India’s leading lending‑tech platform Yubi has integrated CockroachDB to scale tenfold, unify its product suite, and support global expansion—while maintaining cloud neutrality.
Source: PR Newswire
Analysis & Opinion:
-
Scalability & Resilience: CockroachDB’s geo‑partitioning and horizontal scaling ensure Yubi can handle surges in transaction volumes without downtime—a critical factor for mission‑critical credit processes.
-
Compliance & Data Locality: As Yubi enters new jurisdictions, CockroachDB’s data‑locality controls help meet regional data‑sovereignty laws, reducing compliance risks for cross‑border lenders.
-
Strategic Infrastructure Decisions: This partnership signals a broader industry shift toward cloud‑neutral, distributed databases—prioritizing flexibility over vendor lock‑in and aligning with the multi‑cloud strategies of enterprise fintechs.
The Takeaway: A Fintech Mosaic in Motion
Today’s briefs underscore three core themes shaping 2025’s fintech narrative:
-
Geographic Diversification: Fiserv’s move to Kansas and ANNA’s Australian launch illustrate that fintech growth is no longer siloed in legacy tech hubs.
-
Programmable Money & Real‑Time Rails: Circle’s CPN and stablecoin rails are accelerating cross‑border flows, foreshadowing an era where money movement is as frictionless as email.
-
Infrastructure & Data Strategy: From Braviant’s analytics to Yubi’s database overhaul, fintech leaders are doubling down on scalable, compliant, and intelligent back‑end systems to support rapid innovation.
As the industry matures, success will hinge not just on sleek front‑ends but on robust infrastructure, strategic partnerships, and regulatory foresight. Keep watching this space—tomorrow’s Pulse will bring you fresh insights.
The post Fintech Pulse: Your Daily Industry Brief – April 22, 2025 (Fiserv, Circle, Braviant, ANNA Money & Shaype, Yubi) appeared first on News, Events, Advertising Options.
-
Fintech PR4 days agoBybit’s CEO Meets with Vietnam’s Minister of Finance to Support Regulatory Sandbox and Strengthen Crypto Compliance
-
Fintech PR5 days agoYarbo Secures $27M+ Series B Funding to Accelerate Global Growth, Innovation, and Ecosystem Expansion
-
Fintech PR6 days agoDigital Oilfield Market is expected to generate a revenue of USD 38.09 Billion by 2031, Globally, at 5.31% CAGR: Verified Market Research®
-
Fintech PR5 days agoeCig Click Questions Impact of £10 Million Trading Standards Crackdown on Illicit Tobacco and Vaping Trade
-
Fintech PR6 days agoCognoa Advocates for Expanded Insurance Coverage of Canvas Dx as CDC Reports 1 in 31 Children Now Identified with Autism
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief – April 16, 2025 – Featuring RWA Inc and Wolters Kluwer
-
Fintech PR6 days agoCard Payments Market to Reach $38,325.4 billion by 2027 in the short run and $56,379.3 billion by 2033 Globally, at 6.9% CAGR: Allied Market Research
-
Fintech PR4 days ago“Shanghai Summer”: A Living Case of a Next-Generation Consumer Hub